For instance, in sarcomas and glioblastomas, MDM2 amplification correlates with poor prognosis, while in breast cancer, elevated MDM2 levels are associated with reduced disease-free survival, particularly in estrogen receptor-positive tumors (Oliner et al., 2016). This evidence concerns the gene MDM2 and breast cancer.